
Quarterly report 2025-Q3
added 11-17-2025
Zynex Net Income 2011-2026 | ZYXI
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Zynex
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.99 M | 9.73 M | 17 M | 17.1 M | 9.07 M | 9.49 M | 9.55 M | 7.36 M | 69 K | -2.91 M | -6.2 M | -7.3 M | 1.55 M | 1.56 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 17.1 M | -7.3 M | 4.94 M |
Quarterly Net Income Zynex
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -42.9 M | -20 M | -10.4 M | - | 2.38 M | 1.22 M | 10 K | - | 3.59 M | 3.35 M | 1.57 M | - | 4.87 M | 3.35 M | 1.38 M | 8.89 M | 6.11 M | 2.81 M | -706 K | 1.79 M | 1.33 M | 3.02 M | 2.94 M | 2.95 M | 2.03 M | 2.16 M | 2.35 M | 2.62 M | 2.59 M | 2.42 M | 1.92 M | 3.31 M | 2.2 M | 1.5 M | 353 K | 208 K | 532 K | -227 K | 69 K | - | -2.91 M | 2.91 M | -2.91 M | - | -6.2 M | -6.2 M | -6.2 M | - | -738 K | -1.72 M | -304 K | - | 358 K | 473 K | 320 K | - | 591 K | 484 K | -110 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.89 M | -42.9 M | -404 K |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Medical devices industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Bruker Corporation
BRKR
|
113 M | $ 36.74 | - | $ 5.47 K | ||
|
ClearPoint Neuro
CLPT
|
-25.5 M | $ 9.38 | - | $ 266 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
-18.6 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
-81.7 M | - | -26.83 % | $ 2.62 M | ||
|
Cytosorbents Corporation
CTSO
|
-8.2 M | $ 0.59 | - | $ 36.7 M | ||
|
AdaptHealth Corp.
AHCO
|
-70.8 M | $ 12.07 | - | $ 1.63 B | ||
|
Allied Healthcare Products
AHPI
|
-1.94 M | - | 3.58 % | $ 2.21 M | ||
|
Delcath Systems
DCTH
|
2.7 M | $ 9.7 | - | $ 347 M | ||
|
EDAP TMS S.A.
EDAP
|
-21.2 M | $ 3.45 | 1.77 % | $ 129 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
-12.3 M | - | -5.86 % | $ 30.6 M | ||
|
Edwards Lifesciences Corporation
EW
|
1.07 B | $ 81.19 | - | $ 47.5 B | ||
|
FONAR Corporation
FONR
|
12.4 M | $ 18.6 | - | $ 122 M | ||
|
Globus Medical
GMED
|
538 M | $ 88.6 | - | $ 12 B | ||
|
Apollo Endosurgery
APEN
|
-39.8 M | - | - | $ 475 M | ||
|
Helius Medical Technologies
HSDT
|
-8.85 M | $ 1.9 | - | $ 1.15 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
-6.94 M | $ 9.31 | - | $ 717 M | ||
|
Inspire Medical Systems
INSP
|
145 M | $ 54.14 | - | $ 1.59 B | ||
|
IRIDEX Corporation
IRIX
|
-4.44 M | $ 1.0 | - | $ 16.9 M | ||
|
Integer Holdings Corporation
ITGR
|
103 M | $ 85.63 | - | $ 2.97 B | ||
|
OrthoPediatrics Corp.
KIDS
|
-39.6 M | $ 15.94 | - | $ 374 M | ||
|
LENSAR
LNSR
|
-34.3 M | $ 5.89 | -2.81 % | $ 70.4 M | ||
|
CryoLife, Inc.
CRY
|
-16.7 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
-18.3 M | - | -20.74 % | $ 369 K | ||
|
Medtronic PLC
MDT
|
4.66 B | $ 86.28 | - | $ 111 B | ||
|
Align Technology
ALGN
|
421 M | $ 171.87 | - | $ 12.9 B | ||
|
Myomo
MYO
|
-15.6 M | $ 0.7 | - | $ 29.3 M | ||
|
AxoGen
AXGN
|
-15.7 M | $ 32.64 | - | $ 1.5 B | ||
|
Axonics Modulation Technologies
AXNX
|
-59.7 M | - | - | $ 3.31 B | ||
|
Orthofix Medical
OFIX
|
-92.2 M | $ 11.77 | - | $ 466 M | ||
|
Aziyo Biologics
AZYO
|
53.4 M | - | 1.37 % | $ 20.5 M | ||
|
Soliton, Inc.
SOLY
|
-14.5 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.14 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-10.9 M | - | 0.03 % | $ 1.58 B | ||
|
Penumbra
PEN
|
178 M | $ 329.87 | - | $ 12.8 B | ||
|
Misonix, Inc.
MSON
|
-17.4 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-24.9 M | - | - | $ 111 M | ||
|
Insulet Corporation
PODD
|
247 M | $ 203.5 | - | $ 14.3 B | ||
|
Sintx Technologies
SINT
|
-10.4 M | $ 2.53 | 0.4 % | $ 7.02 M | ||
|
Butterfly Network
BFLY
|
-72.5 M | $ 4.13 | -0.24 % | $ 874 M | ||
|
Intersect ENT, Inc.
XENT
|
-72.3 M | - | - | $ 955 M | ||
|
Smith & Nephew plc
SNN
|
524 M | $ 32.63 | - | $ 23.8 B | ||
|
Stryker Corporation
SYK
|
849 M | $ 332.3 | - | $ 127 B | ||
|
Tactile Systems Technology
TCMD
|
19.1 M | $ 24.57 | - | $ 562 M | ||
|
TELA Bio
TELA
|
-38.8 M | $ 0.63 | 5.47 % | $ 29.6 M | ||
|
TransMedics Group
TMDX
|
190 M | $ 104.8 | - | $ 3.56 B | ||
|
Tandem Diabetes Care
TNDM
|
-589 K | $ 19.17 | - | $ 1.3 B | ||
|
BIOLASE
BIOL
|
-20.6 M | - | -13.19 % | $ 166 K | ||
|
BioSig Technologies
BSGM
|
-463 M | - | 37.08 % | $ 85.7 M |